Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
64.05
-3.15 (-4.69%)
Sep 10, 2026, 11:59 AM HKT

Shanghai Henlius Biotech Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Shanghai Henlius Biotech stock has a consensus rating of "Strong Buy" and an average price target of $102.12. The average 1-year stock price forecast is 59.44% higher than the current stock price, while the lowest is $91.81 (+43.34%) and the highest is $120.15 (+87.59%).

Price Target: $102.12 (+59.44%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$91.81$102.12$101.81$120.15
Change+43.34%+59.44%+58.95%+87.59%

Analyst Ratings

The average analyst rating for Shanghai Henlius Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy887767
Buy001111
Hold000000
Sell000000
Strong Sell000000
Total888878

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
CICC
No rating
CICC
Buy
Maintains
$102.91
BuyMaintains$102.91+60.67%Sep 1, 2026
Unknown Analyst
SPDB
No rating
SPDB
Buy
Maintains
$95.10
BuyMaintains$95.10+48.48%Aug 26, 2026
Unknown Analyst
SDIC Securities
No rating
SDIC Securities
Buy
Maintains
$90.22
BuyMaintains$90.22+40.86%Aug 26, 2026
CMB International Securities
CMB International Securities
Buy
Maintains
$101.66
BuyMaintains$101.66+58.72%Aug 25, 2026
Unknown Analyst
Citi
No rating
Citi
Buy
Maintains
$95.20
BuyMaintains$95.20+48.63%Aug 25, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
7.53B
from 6.67B
Increased by 12.89%
Revenue Next Year
7.58B
from 7.53B
Increased by 0.78%
EPS This Year
1.67
from 1.51
Increased by 10.42%
EPS Next Year
1.53
from 1.67
Decreased by -8.00%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
1.68B3.21B5.39B5.72B6.67B7.53B
Revenue Growth
186.34%91.07%67.82%6.11%16.46%12.89%
Gross Profit
1.16B2.37B3.92B4.18B4.98B5.68B
Gross Margin
68.93%73.73%72.64%73.10%74.77%75.52%
Operating Income
-665.25M-628.53M652.95M866.50M817.12M1.05B
Net Income
-984.05M-695.26M546.02M820.47M827.04M933.50M
EPS
----1.511.67
EPS Growth
-----10.42%
Forward PE
--12.5515.9127.5232.86
Free Cash Flow
-857.51M-1.02B-709.99M176.66M-922.42M900.00M
No. Analysts
-----8
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue202620272028
High7.8B
Avg7.5B
Low7.2B

Revenue Growth

Revenue Growth202620272028
High
17.7%
Avg
12.9%
Low
8.5%

EPS Forecast

EPS202620272028
High2.05
Avg1.67
Low1.24

EPS Growth

EPS Growth202620272028
High
35.8%
Avg
10.4%
Low
-17.9%